Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Novartis patent term dabrafenib?Sun pharma bortezomib?What are alcohol's effects on ozempic?Dabrafenib btd date 2023?Pramlintide fda approval date?
See the DrugPatentWatch profile for cosentyx
Yes, Cosentyx (secukinumab) is FDA-approved for active ankylosing spondylitis in adults.[1][2] It targets interleukin-17A to reduce inflammation and symptoms like back pain and stiffness. Clinical trials showed significant improvement in ASAS20 response rates compared to placebo.[2] The standard dose is 150 mg subcutaneous injection every 4 weeks after initial loading doses.[1] Sources [1]: FDA Label for Cosentyx [2]: Novartis Cosentyx Prescribing Information
Other Questions About Cosentyx :